End-of-day quote
Korea S.E.
18:00:00 2024-05-13 EDT
|
5-day change
|
1st Jan Change
|
13,490
KRW
|
+7.06%
|
|
+3.13%
|
-8.11%
|
Fiscal Period: Septiembre |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
295,706
|
206,744
|
226,346
|
160,691
|
92,964
|
207,570
|
Enterprise Value (EV)
1 |
299,141
|
214,378
|
236,330
|
191,999
|
135,320
|
241,663
|
P/E ratio
|
75.3
x
|
21.6
x
|
-12.6
x
|
-8.78
x
|
53.3
x
|
-8.34
x
|
Yield
|
0.32%
|
0.55%
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5.71
x
|
3.09
x
|
2.83
x
|
2.72
x
|
1.25
x
|
2.66
x
|
EV / Revenue
|
5.78
x
|
3.2
x
|
2.95
x
|
3.25
x
|
1.82
x
|
3.1
x
|
EV / EBITDA
|
24.5
x
|
15
x
|
1,147
x
|
-12.8
x
|
22
x
|
232
x
|
EV / FCF
|
69.4
x
|
-47
x
|
-35.9
x
|
-51.3
x
|
-8.24
x
|
122
x
|
FCF Yield
|
1.44%
|
-2.13%
|
-2.79%
|
-1.95%
|
-12.1%
|
0.82%
|
Price to Book
|
4.72
x
|
2.88
x
|
3.79
x
|
3.62
x
|
2.03
x
|
4.22
x
|
Nbr of stocks (in thousands)
|
9,417
|
9,462
|
9,906
|
10,012
|
9,674
|
11,577
|
Reference price
2 |
31,400
|
21,850
|
22,850
|
16,050
|
9,610
|
17,930
|
Announcement Date
|
12/19/18
|
12/18/19
|
12/18/20
|
12/21/21
|
12/20/22
|
12/19/23
|
Fiscal Period: Septiembre |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
51,746
|
66,991
|
80,098
|
59,098
|
74,459
|
78,032
|
EBITDA
1 |
12,188
|
14,326
|
206.1
|
-14,993
|
6,158
|
1,043
|
EBIT
1 |
10,308
|
12,572
|
-3,407
|
-19,778
|
1,256
|
-4,155
|
Operating Margin
|
19.92%
|
18.77%
|
-4.25%
|
-33.47%
|
1.69%
|
-5.32%
|
Earnings before Tax (EBT)
1 |
5,298
|
11,484
|
-16,700
|
-21,617
|
3,501
|
-23,532
|
Net income
1 |
4,017
|
9,951
|
-17,840
|
-18,289
|
6,147
|
-23,045
|
Net margin
|
7.76%
|
14.85%
|
-22.27%
|
-30.95%
|
8.26%
|
-29.53%
|
EPS
2 |
416.8
|
1,012
|
-1,808
|
-1,827
|
180.4
|
-2,150
|
Free Cash Flow
1 |
4,309
|
-4,560
|
-6,587
|
-3,746
|
-16,415
|
1,977
|
FCF margin
|
8.33%
|
-6.81%
|
-8.22%
|
-6.34%
|
-22.05%
|
2.53%
|
FCF Conversion (EBITDA)
|
35.36%
|
-
|
-
|
-
|
-
|
189.48%
|
FCF Conversion (Net income)
|
107.26%
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
100.0
|
120.0
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/19/18
|
12/18/19
|
12/18/20
|
12/21/21
|
12/20/22
|
12/19/23
|
Fiscal Period: Septiembre |
2023 Q1
|
2023 Q2
|
2023 Q3
|
---|
Net sales
1 |
20.07
|
20.48
|
18.47
|
EBITDA
|
-
|
-
|
-
|
EBIT
1 |
0.0858
|
-0.3468
|
0.1217
|
Operating Margin
|
0.43%
|
-1.69%
|
0.66%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
Net income
1 |
-3.588
|
-9.744
|
-0.4159
|
Net margin
|
-17.88%
|
-47.57%
|
-2.25%
|
EPS
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
Announcement Date
|
2/14/23
|
5/15/23
|
8/14/23
|
Fiscal Period: Septiembre |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
3,435
|
7,634
|
9,984
|
31,309
|
42,356
|
34,093
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
0.2819
x
|
0.5329
x
|
48.45
x
|
-2.088
x
|
6.878
x
|
32.68
x
|
Free Cash Flow
1 |
4,309
|
-4,560
|
-6,587
|
-3,746
|
-16,415
|
1,977
|
ROE (net income / shareholders' equity)
|
7.94%
|
12.4%
|
-23.7%
|
-37.9%
|
10.4%
|
-49.5%
|
ROA (Net income/ Total Assets)
|
7.49%
|
6.96%
|
-1.6%
|
-9.46%
|
0.6%
|
-2.04%
|
Assets
1 |
53,625
|
142,994
|
1,113,899
|
193,266
|
1,022,469
|
1,127,320
|
Book Value Per Share
2 |
6,651
|
7,592
|
6,026
|
4,440
|
4,732
|
4,244
|
Cash Flow per Share
2 |
872.0
|
1,055
|
1,382
|
704.0
|
780.0
|
530.0
|
Capex
1 |
2,241
|
15,564
|
7,046
|
4,891
|
3,986
|
1,937
|
Capex / Sales
|
4.33%
|
23.23%
|
8.8%
|
8.28%
|
5.35%
|
2.48%
|
Announcement Date
|
12/19/18
|
12/18/19
|
12/18/20
|
12/21/21
|
12/20/22
|
12/19/23
|
|
1st Jan change
|
Capi.
|
---|
| -8.11% | 129M | | +10.86% | 126B | | -5.36% | 11.27B | | +4.17% | 9.12B | | +40.13% | 5.61B | | -21.47% | 4.75B | | +8.77% | 3.45B | | -6.03% | 2.89B | | -12.05% | 2.07B | | -7.83% | 2.05B |
Medical Devices & Implants
|